Work

Beyond autologous ex vivo CAR-expressing cell therapies: Toward allogeneic and nucleated cell-free delivery systems of CAR

Year: 2026

Type: article

Abstract: engineering. Despite this promise, challenges remain, including cell-specific targeting, control of transgene persistence, immunogenicity, and regulatory considerations. Together, these innovations signal a paradigm shift in the generation and deployment of CAR-based cellular immunotherapies.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201155

Authors: Kathrine S. Rallis, Laura M. Dionisio, Mubin Tarannum, Rizwan Romee, José A. Cancelas

Institution: Dana-Farber Cancer Institute

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900